Thu, May 15, 6:31 PM (39 days ago)
**ProtoKinetix, Incorporated (PKTX) Q1 2025 Financial Summary** ProtoKinetix, Incorporated (PKTX), a development-stage biotechnology company, reported its Q1 2025 financial results, highlighting its ongoing research and development efforts focused on Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, trademarked as AAGP®. **Financial Performance:** - **Revenue:** No significant revenue reported, consistent with its development stage. - **Net Loss:** The company reported a net loss of $97,690,000 for Q1 2025, slightly higher than the $92,026,000 loss in Q1 2024. - **Operating Expenses:** Total operating expenses were $97,690,000, including $36,470,000 in professional fees, $33,810,000 in research and development, and $14,748,000 in general and administrative expenses. - **Cash Flow:** Net cash used in operating activities decreased to $51,970,000 from $57,836,000 in the previous year. Net cash used in investing activities increased to $25,856,000 due to patent application billings. Net cash from financing activities increased to $132,000,000 from $50,000,000, reflecting investor support. - **Cash Position:** As of March 31, 2025, the company had $49,477,000 in cash, up from $(4,697,000) at the end of 2024. **Financial Health and Future Operations:** - **Going Concern:** The company faces substantial doubt about its ability to continue as a going concern due to its history of losses and lack of revenue. It relies on additional equity and/or debt financing to meet cash flow projections and business objectives. - **Capital Raising:** The company issued 13,200,000 shares and warrants in a private placement for $132,000,000 in Q1 2025 and an additional 3,500,000 units in April 2025 for $35,000,000. - **Research and Development:** The company continues to pursue research partners for cost-sharing and engages with institutes offering grants for further studies on the AAGP molecule. - **Uncertainties:** The company's future depends on securing adequate funding, successful research outcomes, and navigating market risks and uncertainties. **Trends and Outlook:** - **Expenses:** Professional fees and research and development costs are significant drivers of operating expenses. - **Cash Flow:** The company's ability to generate positive cash flow is crucial for its sustainability and future growth. - **Funding:** Continued reliance on private placements and equity financing to support operations and research efforts. **Future Impact:** - **Success in securing additional funding will be critical for the company's ability to continue operations and advance its research. - **Positive research outcomes and potential commercialization of the AAGP molecule could significantly impact the company's financial health and market position. **Ticker:** PKTX